Bottom line
RSPH vs VHT: the short answer
RSPH (Invesco S&P 500 Equal Weight Health Care ETF) and VHT (Vanguard Health Care Index Fund) are both etfs.
But VHT is far broader, holding 407 positions to 63 for RSPH, so beyond the top names it adds exposure RSPH doesn't have.
VHT is cheaper at 0.09% vs 0.4% — a difference of $31 a year per $10,000 invested.
Over five years, VHT returned +7.2% a year vs +4.7% for RSPH (reporting dates differ).
Updated Nov 19, 2026
RSPH vs VHT side by side
| RSPH | VHT | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Invesco | Vanguard |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.4% | 0.09% |
| Annual cost per $10k | $40 | $9 |
| 10-yr cost on $10k (prospectus) | $505 | $115 |
| Max front load | None | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +9.3% | +2.7% |
| 5-yr return (annualized) | +4.7% | +7.2% |
| 10-yr return (annualized) | +8.2% | +8.8% |
| Best quarter | +17.5% | +16.5% |
| Worst quarter | −14.3% | −13.1% |
| Net assets (fund) | $766.9M | $19.0B |
| Number of holdings | 63 | 407 |
| Portfolio turnover | 24% | 4% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RSPH | VHT | Difference |
|---|---|---|---|
| 2024 | −0.8% | +2.7% | −3.5% |
| 2023 | +3.9% | +2.5% | +1.5% |
| 2022 | −9.2% | −5.5% | −3.7% |
| 2021 | +23.0% | +20.5% | +2.5% |
| 2020 | +18.9% | +18.2% | +0.7% |
| 2019 | +25.3% | +22.0% | +3.4% |
| 2018 | −0.3% | +5.6% | −5.9% |
| 2017 | +23.4% | +23.3% | +0.1% |
| 2016 | −4.5% | −3.3% | −1.2% |
| 2015 | +8.2% | +7.2% | +1.0% |
Source: Fund prospectus bar charts
Holdings overlap
7 of RSPH's top 25 holdings also appear in VHT's top 25.
| Holding | RSPH | VHT |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 1.96% | 1.00% |
| Thermo Fisher Scientific Inc. | 1.84% | 2.93% |
| Abbott Laboratories | 1.83% | 2.35% |
| Bristol-Myers Squibb Co. | 1.82% | 1.84% |
| Amgen Inc. | 1.77% | 2.87% |
| AbbVie Inc. | 1.73% | 6.09% |
| Cencora, Inc. | 1.71% | 0.79% |
Source: SEC Form N-PORT
RSPH top 10
- Bio-Techne Corp. — 2.13%
- IQVIA Holdings Inc. — 2.00%
- Baxter International Inc. — 1.99%
- Regeneron Pharmaceuticals, Inc. — 1.96%
- Mettler-Toledo International Inc. — 1.94%
- Charles River Laboratories International, Inc. — 1.93%
- Veeva Systems Inc. — 1.93%
- DaVita Inc. — 1.87%
- Moderna, Inc. — 1.85%
- Thermo Fisher Scientific Inc. — 1.84%
VHT top 10
- Eli Lilly & Co — 14.04%
- Johnson & Johnson — 8.47%
- AbbVie Inc — 6.09%
- UnitedHealth Group Inc — 5.45%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 2.93%
- Amgen Inc — 2.87%
- Gilead Sciences Inc — 2.64%
- Intuitive Surgical Inc — 2.38%
- Pfizer Inc — 2.35%
FAQ
What is the difference between RSPH and VHT?
Which is cheaper, RSPH or VHT?
Should I own both RSPH and VHT?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.